[{"id":"8394813c-9f2d-4565-9201-f9b99aa9b390","acronym":"","url":"https://clinicaltrials.gov/study/NCT02543879","created_at":"2021-01-18T12:18:27.959Z","updated_at":"2024-07-02T16:35:28.491Z","phase":"Phase 1","brief_title":"Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies","source_id_and_acronym":"NCT02543879","lead_sponsor":"Forma Therapeutics, Inc.","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • CC-95775"],"overall_status":"Completed","enrollment":" Enrollment 94","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2023-11-21"},{"id":"b00cf327-6db5-41ff-a939-16acf28517b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04089527","created_at":"2021-01-18T20:00:55.948Z","updated_at":"2024-07-02T16:36:17.721Z","phase":"Phase 1b","brief_title":"Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT04089527","lead_sponsor":"Celgene","biomarkers":" GLI1","pipe":"","alterations":" ","tags":["GLI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CC-95775"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 10/24/2019","start_date":" 10/24/2019","primary_txt":" Primary completion: 10/25/2021","primary_completion_date":" 10/25/2021","study_txt":" Completion: 10/25/2021","study_completion_date":" 10/25/2021","last_update_posted":"2022-02-01"}]